Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase

Espié, Marc; Daurès, Jean‐Pierre; Chevallier, Thierry; Marès, P.; Micheletti, Marie-Christine; Reilhac, P. De

doi:10.1080/09513590701382104

Cited by 40 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the association of breast cancer risk and HRT is inconclusive. Some studies discovered an increased breast cancer risk in post-menopausal women related to HRT (Beral and Million Women Study Collaborators, 2003;Stahlberg et al, 2004) while other research did not (Espié, et al, 2007;Cortés-Prieto and Juez-Martel, 2007). Since HRT has become more significant with increasing age, it is important for women to understand the advantages and disadvantages of hormone therapy, so that fears can be cleared (Beckmann et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer: Knowledge and Perceptions of Chinese Women in Hong Kong

Yan¹

2009

GJHS

View full text Add to dashboard Cite

This study explored the knowledge of breast cancer risk factors and employed the Health Belief Model (HBM) to examine the perception and barriers of breast cancer screenings of Hong Kong Chinese women using a structured questionnaire. Of the 496 respondents, 70.8% and 77.0% considered a family history of breast cancer and prior history of benign beast problems as risk factors respectively. However, over 40% were unsure of other risk factors including age, early age at menstruation, late age at menopause, childlessness and oral contraceptive use. About 80% regarded breast cancer as a serious illness and 88.7% acknowledged that both mammography and breast self examination (BSE) could help early detection of the disease. Nevertheless about 68% had never had a mammogram, and the most important perceived barriers were not knowing how the test was done (81.3%) and the cost (63.0%). Only 31.9% did not practice BSE, and not knowing how to perform BSE was the primary perceived barrier.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast Cancer: Knowledge and Perceptions of Chinese Women in Hong Kong

Yan¹

2009

GJHS

View full text Add to dashboard Cite

show abstract

“…Window of opportunity studies to assess the effect of antiestrogen therapies, alone and in combination with micronized progesterone (prometrium) or a progestin (megestrol acetate) in patients with newly diagnosed ER and PR-positive breast cancer are currently being developed in Australia and UK. In the context of these trials, it is worth noting that although synthetic progestins have been associated with increased risk of developing breast cancer in the context of menopausal hormone therapy, in contrast, other studies have shown that hormone replacement therapies using native progesterone have resulted in no change or a slight decrease in breast cancer incidence (de Lignieres et al 2002, Fournier et al 2005, Espie et al 2007, Fournier et al 2008, Schneider et al 2009). …”

Section: Contemporary Strategies For Improving the Treatment And Outcmentioning

confidence: 99%

Pushing estrogen receptor around in breast cancer

Lim

Tarulli

Portman

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

The estrogen receptor-α (herein called ER) is a nuclear sex steroid receptor (SSR) that is expressed in approximately 75% of breast cancers. Therapies that modulate ER action have substantially improved the survival of patients with ER-positive breast cancer, but resistance to treatment still remains a major clinical problem. Treating resistant breast cancer requires co-targeting of ER and alternate signalling pathways that contribute to resistance to improve the efficacy and benefit of currently available treatments. Emerging data have shown that other SSRs may regulate the sites at which ER binds to DNA in ways that can powerfully suppress the oncogenic activity of ER in breast cancer. This includes the progesterone receptor (PR) that was recently shown to reprogram the ER DNA binding landscape towards genes associated with a favourable outcome. Another attractive candidate is the androgen receptor (AR), which is expressed in the majority of breast cancers and inhibits growth of the normal breast and ER-positive tumours when activated by ligand. These findings have led to the initiation of breast cancer clinical trials evaluating therapies that selectively harness the ability of SSRs to 'push' ER towards anti-tumorigenic activity. Our review will focus on the established and emerging clinical evidence for activating PR or AR in ER-positive breast cancer to inhibit the tumour growth-promoting functions of ER.

show abstract

“…However, it seems like this risk is conferred first and foremost to women previously relatively healthy, 107 and not to those with a previous cardiovascular event. 122,123 The adjusted RR for stroke in a prospective observational study (the Nurses Health Study) among women using HRT (CEE+MPA) was 0.54 (95% confidence interval [CI]: 0.28, 1.06), 1.35 (CI: 1.08, 1.68) and 1.63 (CI: 1.18, 2.26), respectively, among users of CEE doses of 0.3 mg, 0.625 mg or ≥1.25 mg. 8 Here progestogen also seems to play a role as when analyses were confined to women taking 0.625 mg CEE only, the RR was 1.24 (95% CI: 0.95, 1.62), rising to an RR of 1.54 (95% CI: 1.12, 2.11) for women taking CEE+MPA.…”

Section: Strokementioning

confidence: 94%

“…This effect is reduced after cessation of HRT and seems to largely, if not wholly, disappear after approximately 5 years, 106 although a recent study claimed this to be the case after only 2.5 years. 107 Nevertheless, it is generally believed that HRT increases the risk of breast cancer, although the use of HRT is not associated with a worse outcome. 108 In fact, HRT before the diagnosis of breast cancer has even been shown to result in more favourable primary tumours, with a lower incidence of recurrences and a better overall survival rate.…”

Section: Breast Cancermentioning

confidence: 99%

Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg

Johansen

Qvigstad

2008

Adv Therapy

View full text Add to dashboard Cite

The menopausal transition is associated with several symptoms, for which both non-pharmacological and pharmacological measures are available to provide relief. However, present knowledge indicates that the former is not highly effective, and that the latter, in terms of systemic oestrogen and progestogen-based hormone replacement therapy (HRT), although being effective (e.g. on vasomotor symptoms, bleeding control, bone mineral density, vaginal atrophy and quality of life), can be associated with some caveats. Amongst these are an increased risk for coronary heart disease, breast cancer, venous thromboembolism and stroke. In recent years, literature has indicated a dose dependency for HRT on some of the caveats, hence authorities (Food and Drug Administration, and the European Medicines Agency) and menopause societies (International Menopause Society and North American Menopause Society) now recommend that women deemed in need of HRT should receive the lowest possible dose without compromising the effect of symptom relief. Estradiol 0.5 mg/norethisterone acetate (NETA) 0.1 mg, despite being a lower dose than conventional hormones, is a compound, among a few other low-dose options, that can be used in such therapy. As a first-line oral option, it has demonstrated its effectiveness (which seems comparable to other compounds), with high tolerability and, apparently, no safety concerns, in a 6-month study. Further long-term clinical trials and observational studies are mandatory in order to capture any potential harm as well as to elucidate this compound's full potential. Following a thorough literature search using PubMed and MEDLINE from the earliest publication dates through to January 2008, including results from various types of clinical trials and statements on HRT, we review the rationale for these recommendations. We also review the effects and safety of a novel 'ultra-low-dose' oral continuous combined HRT tablet, estradiol 0.5 mg/NETA 0.1 mg.

show abstract

Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase

Abstract: No evidence was found for an increased risk of breast cancer in women exposed to HRT compared with non-exposed women.

Cited by 40 publications

References 10 publications

Breast Cancer: Knowledge and Perceptions of Chinese Women in Hong Kong

Breast Cancer: Knowledge and Perceptions of Chinese Women in Hong Kong

Pushing estrogen receptor around in breast cancer

Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg

Contact Info

Product

Resources

About